

Stent versus Coronary Artery Bypass Surgery in Multi-Vessel and Left Main Coronary Artery Disease: A Meta-Analysis of Randomized Trials with Subgroups Evaluation

Pedro José Negreiros de Andrade,^{1,2} João Luiz de Alencar Araripe Falcão,^{1,2} Breno de Alencar Araripe Falcão,^{1,2} Hermano Alexandre Lima Rocha^{1,2}

Hospital Dr. Carlos Alberto Studart Gomes de Messejana,¹ Fortaleza, CE – Brazil Universidade Federal do Ceará,² Fortaleza, CE – Brazil

Abstract

Background: Comparison between percutaneous coronary intervention (PCI) using stents and Coronary Artery Bypass Grafting (CABG) remains controversial.

Objective: To conduct a systematic review with meta-analysis of PCI using Stents versus CABG in randomized controlled trials.

Methods: Electronic databases were searched to identify randomized trials comparing PCI using Stents versus CABG for multi-vessel and unprotected left main coronary artery disease (LMCAD). 15 trials were found and their results were pooled. Differences between trials were considered significant if p < 0.05.

Results: In the pooled data (n = 12,781), 30 days mortality and stroke were lower with PCI (1% versus 1.7%, p = 0.01 and 0.6% versus 1.7% p < 0.0001); There was no difference in one and two year mortality (3.3% versus 3.7%, p = 0.25; 6.3% versus 6.0%, p = 0.5). Long term mortality favored CABG (10.6% versus 9.4%, p = 0.04), particularly in trials of DES era (10.1% versus 8.5%, p = 0.01). In diabetics (n = 3,274) long term mortality favored CABG (13.7% versus 10.3%; p < 0.0001). In six trials of LMCAD (n = 4,700) there was no difference in 30 day mortality (0.6% versus 1.1%, p = 0.15), one year mortality (3% versus 3.7%, p = 0.18), and long term mortality (8.1% versus 8.1%) between PCI and CABG; the incidence of stroke was lower with PCI (0.3% versus 1.5%; p < 0.001). Diabetes and a high SYNTAX score were the subgroups that influenced more adversely the results of PCI.

Conclusion: Compared with CABG, PCI using Stents showed lower 30 days mortality, higher late mortality and lower incidence of stroke. Diabetes and a high SYNTAX were the subgroups that influenced more adversely the results of PCI. (Arq Bras Cardiol. 2019; 112(5):511-523)

Keywords: Myocardial Revascularization/mortality; Percutaneous Coronary Intervention; Drug-Eluting Stents; Stents; Coronary Vessels; Randomized Controlled Trial; Meta-Analysis.

Introduction

Percutaneous coronary intervention (PCI) using stents and coronary artery bypass grafting (CABG) are well-accepted alternatives for treatment of coronary artery disease (CAD). A large number of randomized controlled trials (RCT) comparing the two procedures were published.¹⁻²³ Most studies were underpowered to evaluate isolated endpoints like death, stroke and acute myocardial infarction (AMI). Several meta-analyses were subsequently carried out, pooling results in order to overcome this limitation.²⁴⁻³¹ The largest meta-analysis included a limited number of drug-eluting stent (DES) era trials and/or

Mailing Address: Pedro José Negreiros de Andrade •

Rua Francisco Holanda, 992 apt. 1101. Postal Code 60130-040, Dionísio Torres, Fortaleza, CE – Brazil

E-mail: pedroneg@gmail.com, pedroneg@gmail.com

Manuscript received March 05, 2018, revised manuscript August 06, 2018, accepted September 05, 2018

DOI: 10.5935/abc.20190027

included also single vessel disease and balloon era trials. On the other side, modern meta-analysis included a lower number of trials (only of DES era) and evaluated specific group of patients.²⁸⁻³² The objective of this study was to perform a systematic review of RCT comparing stents (bare-metal and drug-eluting) versus CABG in multi-vessel and/or left main coronary disease (LMCAD) pooling data of mortality at different periods of time and using meta-regression analysis to evaluate sub-groups.

Methods

Search strategies

Randomized studies comparing PCI with Stents versus CABG in multivessel lesions and/or obstruction of left main CAD published between January 1990 and December 2017 were searched in the databases MEDLINE and Cochrane library and in bibliographic references published on the subject. The search terms used were: "coronary stents" and "coronary artery bypass surgery" and "randomized controlled trial".

Inclusion criteria

Clinical trials were included in the review if they were randomized, if had compared PCI with stents versus CABG, if included exclusively multi-vessel and/or LMCAD and if had a follow up of at least 1 year. We did not limit our search to DES trials because bare-metal stents (BMS) are still frequently used in many developing countries, had the peculiarity of evaluating patients with less complex coronary artery disease and there is no definitive evidence that BMS are inferior to DES in the outcome mortality. Figure 7 show a flow diagram of the search strategy in the databases. We identified a total of 15 RCT that satisfied the requirements: AWESOM¹, ERACI II, ^{2,3} MASS II, ⁴⁻⁶ SOS, 7,8 ARTS, 9,10 LE MANS, 11 SYNTAX, 12-14 CÁRDia, 15 Boldriot et al.,¹⁶ PRECOMBAT,^{17,18} Va-Cards,¹⁹ FREEDOM,²⁰ BEST,²¹ NOBLE^{22} and EXCEL^{23} Three reviewers (PJNA, ATA and JLAF) assessed the quality of the studies using the Cochrane Collaboration's tool.

Data extraction

Two reviewers (JLAAF and PJNA) obtained the data from the studies, examining abstracts, results, tables, appendices and figures. A third author (BAAF) checked the results.

The main outcomes evaluated were all case-mortality, stroke, AMI and new revascularization. Mortality was divided into early mortality, mortality at one year and late mortality. Early mortality was defined as percentage of deaths that occurred in the first 30 days after the procedure, including deaths after randomization but before the procedure. Late mortality was defined as percentage of deaths reported in the last publication, after at least three years of follow-up. For the incidence of stroke, we considered the events occurring up to 1 year after the procedure. In twelve studies we obtained the results up to 30 days, in 2 studies ^{9,12} up to 1 year and in one ²¹ this observation was unavailable. For the incidence of myocardial infarct, we considered the reported up to one year of the procedure. AMI were reported in 13 trials.²⁻⁵⁻¹⁵ We did not consider in the pooled data the results of NOBLE because it excluded perioperative myocardial infarct in the majority of the patients.

New revascularization was divided in any form of new revascularization (PCI or CABG) and new revascularization by alternative procedure (PCI for patients of the CABG group or CABG for the patients of the PCI group).

Data synthesis

The characteristics of patients from the eligible studies were obtained through a weighted average of published data. For pooling results of mortality and stroke, the numerator was the number of events and the denominator the total of patients. The total of patients was the number of patients effectively followed, including the deaths. Trials were divided into DES era trials and BMS era trials. Trials that used both types of stents^{11,15} were classified as DES era trials. We evaluated separately the results of studies in the left main coronary artery and late mortality in the subgroup of patients with diabetes. We also performed analysis of combined major adverse cardiac and cerebrovascular events (MACCE) and assessed the variables age, gender, presence of diabetes, SYNTAX score,

and compromised ejection fraction in subgroups based on data published in five trials. Combined MACCE comprised death, AMI, and new revascularization. In order to aggregate the outcomes of mortality and stroke, as well as those of MACCE (in subgroups), we considered whenever possible the absolute number of events and the number of patients followed up. Otherwise, percentages were transformed into absolute numbers.

Statistical analysis

We measured the relative risk and the risk difference after grouping the results of each outcome. In order to assess the statistical significance of the differences between the DES and the surgery groups, we performed a meta-analysis using the Mantel-Haenszel method, with a random-effect model. We calculated the heterogeneity of the studies using Cochran's Q test and the significance of the measure of the meta-analytic effect using the Z test. Finally, we performed a meta-regression analysis using diabetes, age, gender, ejection fraction, and syntax scores as factors. The differences between the results in the PCI and CABG groups were considered significant if p<0.05. The statistical analyses were performed using the program Review Manager (RevMan), version 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) and SPSS for Windows v 23, IBM Inc. In order to represent the heterogeneity of the studies, we constructed Forest plots. We used the risk difference to plot these graphs since this is a more stable index. The possibility of publication bias was assessed by visual inspection of funnel plots.

Results

Studies Characteristics

The studies (table 1) included a total of 12,781 patients (6,382 in the CABG group and 6,399 in the PCI group). All studies were, considered of guality A or B in terms of adequate randomization, adequate concealment and inexistence of selection bias, but not in terms of adequate making. In all studies, the PCI and CABG groups were similar, with the exception of VaCards where the PCI group had a higher incidence of the previous revascularization (in most of the cases a previous PCI) and showed a higher percentage of patients with ejection fraction < 55%. The mean age of the patients was 64 years; 74% were male; 42% were diabetics; 28% were smokers; 64% were hypertensive. Unstable angina was the clinical presentation in 34%; mean ejection fraction was 58%. With the exception of AWESOME, all studies tended to exclude patients with previous CABG. The mean SYNTAX score was 26. According to number of arteries affected 20% had two vessel disease, 43% had three-vessel disease and 37% had LMCAD (alone or associated with diseases of other arteries). In the CABG group, at least one arterial graft was used in 90% of the patients. In trials of the BMS era surgery was done almost always using on-pump technique; in trials of the era, the DES off-pump technique was used in 28% of the patients. Some characteristics of the studies deserve special mention:

ERACI II included more them 90% of patients with unstable angina. AWESOME included only patients with high surgical risk; MASS II included predominantly stable angina and had a clinical arm; LE MANS used drug-eluting and BMS, reserving the DESs for left main coronary arteries with a reference diameter < 3.8 mm; CARDia used initially BMS and only assessed patients with diabetes and multivessel disease; SYNTAX evaluated left main coronary artery obstruction and multivessel disease and used first-generation DESs (TAXUS); FREEDOM and VA CARDS exclusively assessed patients with diabetes and multivessel disease; BEST evaluated patients with multivessel disease and used only everolimus-eluting stents; the study by Boudriot et al. evaluated left main coronary artery obstruction and used only sirolimus-eluting stents; EXCEL evaluated left main coronary artery obstruction and used only everolimus-eluting stents; NOBLE evaluated left main coronary artery obstruction and used mostly a biolimus-eluting stent.

Outcomes

The results are summarized in Figures 1 to 6. Regarding 30-day mortality, the results favoured PCI (1% versus CABG 1.7%, p = 0.01), but the trials showed moderate overall heterogeneity ($I^2 = 49\%$). The heterogeneity was particularly higher in BMS era trials ($I^2 = 83\%$) and could be attributed to the significant inferior results of surgery in ERACI II and AWESOME. The incidence of stroke was lower with PCI (0.6% versus CABG 1.7%, p < 0.0001), with trials showing low heterogeneity ($I^2 = 0$). There was no difference in mortality up to one year (PCI 3.3% versus CABG 3.7%, p = 0.25) or up to two year (PCI 6.3% versus CABG 6.0%, p = 0.5). Long-term mortality showed a trend to superiority of CABG (10.6% versus 9.4%, p = 0.04), with trials showing moderate heterogeneity ($I^2 = 25\%$). The differences were significant in trials of DES era (10.1% versus 8.5%, p = 0.01). After excluding FREEDOM (that included only diabetics) the overall difference in long-term mortality between PCI and CABG became not significant (10.2% versus 9.4%, p = 0.17). The incidence of myocardial infarct was lower with CABG (PCI 6.4 % versus CABG 5.3% at one year and PCI 8,8% versus CABG 6.7 % after 3 or more years), but the trials showed high heterogeneity.

In 6 studies of LMCAD (n = 4700), there was no difference in 30 days mortality (0.6% versus 1.1%, p = 0.15) between PCI and CABG, but the incidence of stroke was significantly lower after PCI (0.3% versus 1.1%, p = 0.007). There was no difference in one-year mortality (3% versus 3.7%, p = 0.18) or long-term mortality (8.1% versus 8.1%) between PCI and CABG.

Nine trials (n = 4394) reported long-term mortality in diabetics (AWESOME, ARTS, ERACII, MASS II, SOS, SYNTAX, CARDia, FREEDOM and BEST). After pooling of results, CABG was associated with significantly lower long-term mortality (13.7% versus 10.3% CABG, p < 0.0001); After excluding the diabetic patients of these nine trials the overall difference in long-term mortality between PCI and CABG was no longer significant (9.2% versus 9.2%).

The data regarding new revascularization are shown in figure 5. The superiority of surgery over PCI was consistent

in all 15 trials. However, if we consider the risk of new revascularization by alternative procedure there was a trend to superiority of PCI in ARTS and in all studies of DES era.

Subgroups results

Five trials reported long-term results of major Adverse Composite Events (death, myocardial infarct and stroke) in subgroups. In three of them (SYNTAX, PRECOMBAT and BEST) the results were obtained through the collaborative meta-analysis of Lee et al.²⁴ (Figure 4). The pooled data showed that CABG, compared to PCI, was associated with a lower incidence of MACCE (18.4% vs 14.4%, p < 0.0001). The subgroups in which PCI had worse results, when compared with CABG, by meta-regression analysis were presence of diabetes (23% versus 17.5, p < 0.0001) and a high SYNTAX score (22.7 vs. 16.3%, p = 0.001). There was no difference between PCI and CABG in non-diabetics (14.1% versus 12.3%, p = 0.11), low SYNTAX score patients (14.1% vs. 13.3% scores, p = 0.4) and LMCAD patients (14.7% vs 14.1%, p = 0.5). Female sex and old age less significantly influenced the results. Left ventricular dysfunction did not influence the results. Figure 5 shows that the meta-Adjusted value of p for diabetes was 0.03 (adjusted for age or sex) and 0.09 (adjusted for SYNTAX score). The same figure shows that the meta-adjusted value of p for SYNTAX score was 0.03 (adjusted for diabetes).

Discussion

To our knowledge this meta-analysis is the most comprehensive and up to date overview of randomized trials that compared coronary stents (DES and BMS) versus CABG. It is also the only major meta-analysis of the stent era that evaluated mortality at different times (up to 30 days, up to one year and after three or more years of follow-up). Another peculiarity of the present meta-analysis was the statistical meta-regression analysis of sub-groups.

The superiority of PCI on 30 days mortality is in accord with the New York state Registry³³ and with the meta-analysis of Palmerini et al.³² This superiority should be seen with caution considering the heterogeneity of the trials and cannot be extended to patients with high SYNTAX score, considering the mortality curve of the study of Cavalcante et al.³⁰ The significant difference, favoring PCI found in the incidence of stroke is a relevant finding. A recent study showed that, after death (relative weight 0.23), stroke is the most feared event for patients (relative weight 0.18), being considered more important them longevity (relative weight 0.17), myocardial infarct (relative weight 0.14) and risk of repeat revascularization (relative weight 0.11).³⁴The lack of difference in intermediate mortality was an expected finding, having been reported in almost all trials.

The trend superiority of surgery in long-term mortality was shown in other meta-analysis^{26,29,31} and is probably related to the higher percentage of diabetics in recent trials. Our results of long-term mortality (HR 1.13) were similar to the results of Smit el al.²⁶ (HR 1.11) and Lee et at.²⁹ (HR 1.18). They were much less unfavourable to PCI them the reported by Benedetto et al (HR 1.5).³¹ The reason for this is that

67		5	~	6	4	-	-	4		Ŧ
0	0	15	31	46	64	19	ND	64	29	16
65	53	QN	59	QN	60	65	QN	59	57	е0
36	32	28	22	ND	45	30	ND	42	37	18
BMS. Clinical arm	BMS and DES DES if LM < 3.8	DES (Taxus)	BMS and DES. Only diabetics.	DES (Sirolimus)	DES (Everolimus)	DES. Only diabetes	DES. Only diabetics	DES. (Everolimus)	DES. (Everolimus)	DES (Biolimite)
Two and three vessel disease	Left main coronary disease	Left main and three vessel disease	Two and three vessel disease	Left main coronary disease	Left main coronary disease	Two and three vessel disease	Two and three vessel disease	Two and three vessel disease	Left main coronary disease	l aft main coronany disease
408	105	1800	510	201	600	1900	198	880	1905	087
1995-2000	2001-2004	2005-2007	2002-2007	2003-2009	2003-2009	2005-2010	2006-2010	2008-2013	2010-2014	2008-2015
South America (Brazil)	Europe (Poland)	Europe and USA	Europe (United Kingdom)	Europe (Germany)	Asia (Korea)	International	North America (USA)	Asia (Korea)	International	Europe
MASS II	LEMANS	SYNTAX	CARDia	Boudriot et al	PRECOMBAT	FREEDOM	Va-Cards	BEST	EXCEL	

9

8 42 00 <u>1</u>0

45

25 8

80

8

DES (Biolimus)

Left main coronary disease Left main coronary disease

2010-2014 2008-2015

International Europe

NOBLE EXCEL

982

Implantation in the Treatment of Patients with Multivessel Coronary Artery Disease; PRECOMBAT: Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease; EXCEL: Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization; NOBLE: Nordic-Baltic-British Left Main Revascularization Study. Boldriot et al: J Am Coll Cardiol. 2011; 57: 538-545. DES: drug-eluting stent; BMS: bare-metal stent. Left main stenting; FREEDOM: Future Revascularization Evaluation in Patients with Diabetes Mellitus; Va-Cards: Coronary Artery Revascularization in Diabetes in VA Hospitals; BEST; Bypass Surgery and Everolinus-Eluting Stent AWESOME: Angina with extremely severe outcomes; ERACI II: Argentine randomized study: coronary angioplasty with stenting versus coronary bypass surgery in patients with multivessel disease; MASS II: Medicine, Angioplasty or Surgery Study; ARTS: Arterial Revascularization Therapies Study; SOS: Stent or Surgery trial. SYNTAX: Synergy between PCI with Taxus and Cardiac Surgery: CARDia: Coronary artery revascularization in diabetic; Le Mans:

Andrade et al Stent versus CABG: a meta-analysis

Table 1 – Overview of clinical trials

Diabetics (%)

surgery (%) Off pump

Average ejection fraction (%)

angina (%) Unstable

Characteristics

Disease extension

Number of Patients

recruitment

Origin

Study

Period of

33

0

45

36

BMS. Previous CABG included

Two and three vessel disease

454

1995-2000

North America (USA)

AWESOME

Two and three vessel disease

1205

1997-2000

International

ARTS

5

0

6

8

BMS. Majority two

vessel disease BMS. Majority

17

0

₽

92

unstable angina

Two and three vessel disease

450

1996-1998

South America (Argentina)

ERACI II

15 8 25 35

ო

ᢓ

g

BMS. Majority two vessel disease

Two and three vessel disease

988

1995-1999

Europe and Canada

SOS

	Stent	CABG		Risk Difference	Risk Difference
Study or Subgroup	Events Total	Events Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
0 day mortality					
.2.1 BMS					
WESOME 2001	7 222	12 232	5.0%	-0.02 [-0.06, 0.02]	
ERACI II 2001 //ASS II 2004	2 225 5 205	12 225 5 203	5.0% 4.5%	-0.04 [-0.08, -0.01] -0.00 [-0.03, 0.03]	
SOS 2004	4 488	1 500	10.9%	0.01 [-0.00, 0.02]	-
Subtotal (95% CI)	1140	1160		-0.01 [-0.02, 0.00]	•
otal events	18	30			
leterogeneity: Chi ² = 1 est for overall effect: Z			ó		
.2.2 DES					
BEST 2015	3 438	7 442	9.7%	-0.01 [-0.02, 0.00]	
Boudriot et al 2011	0 100	1 101	2.2%	–0.01 [–0.04, 0.02]	
EXCEL 2016	9 948	10 957	21.0%	-0.00 [-0.01, 0.01]	•
REEDOM 2012 E MANS 2008	8 953 0 52	15 947 2 53	20.9% 1.2%	-0.01 [-0.02, 0.00] -0.04 [-0.10, 0.02]	
OBLE 2016	2 592	7 592	13.0%	-0.01 [-0.02, 0.00]	
RECOMBAT 2011	4 300	9 300	6.6%	-0.02 [-0.04, 0.01]	
ubtotal (95% CI)	3383	3392	74.7%	–0.01 [–0.01, –0.00]	•
otal events eterogeneity: Chi ² = 3	26	51 72): 12 - 0%			
est for overall effect: Z	, (i	<i>, , , , , , , , , ,</i>			
otal (95% CI)	4523	4552	100.0%	-0.01 [-0.01, -0.00]	•
otal events	44	81		- · · -	
leterogeneity: Chi ² = 1				-0.2	-0.1 0 0.1 0.2
est for overall effect: Z est for subgroup differe			(7) · 12 − 00		Favours stent Favours CABG
0		o, un i (p. 0.0	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	•	
Stroke .1.1 BMS					1
ARTS 2001	9 600	13 605	10.1%	-0.01 [-0.02, 0.01]	
WESOME 2001	2 222	3 232	3.8%	-0.00 [-0.02, 0.02]	
RACI II 2001	0 225	2 225	3.8%	-0.01 [-0.02, 0.01]	
MASS II 2004	2 205	6 203 10 500	3.4%	-0.02 [-0.05, 0.01]	
	E 100	10 500	8.3%	-0.01 [-0.02, 0.01]	
SOS 2002 Subtotal (95% CI)	5 488 1740		29.4%	-0.011-0.020.001	
ubtotal (95% Cl)	5 488 1740 18	1765 34	29.4%	-0.01 [-0.02, -0.00]	•
ubtotal (95% CI) otal events leterogeneity: Chi ² = 1.	1740 18 .00, df = 4 (p = 0.	1765 34 91); I ² = 0%	29.4%	-0.01 [-0.02, -0.00]	•
Subtotal (95% CI) Total events leterogeneity: Chi ² = 1.	1740 18 .00, df = 4 (p = 0.	1765 34 91); I ² = 0%	29.4%	-0.01 [-0.02, -0.00]	•
Subtotal (95% CI) total events leterogeneity: Chi ² = 1. test for overall effect: Z	1740 18 .00, df = 4 (p = 0.	1765 34 91); I ² = 0%		-0.01 [-0.02, -0.00]	•
ubtotal (95% CI) tal events eterogeneity: Chi ² = 1. est for overall effect: Z 1.2 DES budriot et al 2011	1740 18 .00, df = 4 (p = 0. 2 = 2.17 (p = 0.03) 0 100	1765 34 91); I ² = 0% 2 101	1.7%	-0.02 [-0.05, 0.01]	•
ubtotal (95% CI) otal events eterogeneity: Chi ² = 1. ast for overall effect: Z 1.2 DES oudriot et al 2011 ARDIA 2010	1740 18 .00, df = 4 (p = 0. 2 = 2.17 (p = 0.03) 0 100 1 254	1765 34 91); I ² = 0% 2 101 7 248	1.7% 4.2%	-0.02 [-0.05, 0.01] -0.02 [-0.05, -0.00]	•
ubtotal (95% CI) tal events eterogeneity: Chi ² = 1. sst for overall effect: Z 1.2 DES oudriot et al 2011 ARDIA 2010 XCEL 2016	1740 18 .00, df = 4 (p = 0. 2 = 2.17 (p = 0.03) 0 100 1 254 5 948	1765 34 91); I ² = 0% 2 101 7 248 12 957	1.7% 4.2% 16.0%	-0.02 [-0.05, 0.01] -0.02 [-0.05, -0.00] -0.01 [-0.02, 0.00]	• • • •
Subtotal (95% Cl) otal events leterogeneity: Chi ² = 1. Test for overall effect: Z .1.2 DES Boudriot et al 2011 CARDIA 2010 EXCEL 2016 REEDOM 2012 E MANS 2008	1740 18 .00, df = 4 (p = 0. 2 = 2.17 (p = 0.03) 0 100 1 254	1765 34 91); I ² = 0% 2 101 7 248	1.7% 4.2%	-0.02 [-0.05, 0.01] -0.02 [-0.05, -0.00]	• • • •
Subtotal (95% CI) Total events leterogeneity: Chi ² = 1. Test for overall effect: Z .1.2 DES Boudriot et al 2011 ARDIA 2010 EXCEL 2016 REEDOM 2012 E MANS 2008 IOBLE 2016	1740 18 .00, df = 4 (p = 0. 2 = 2.17 (p = 0.03) 0 100 1 254 5 948 3 953 0 52 1 593	$\begin{array}{c} 1765\\ 34\\ 91); \ l^2=0\%\\ 2 & 101\\ 7 & 248\\ 12 & 957\\ 16 & 947\\ 2 & 53\\ 4 & 592\end{array}$	1.7% 4.2% 16.0% 16.0% 0.9% 10.0%	-0.02 [-0.05, 0.01] -0.02 [-0.05, -0.00] -0.01 [-0.02, 0.00] -0.01 [-0.02, -0.00] -0.04 [-0.10, 0.02] -0.01 [-0.01, 0.00]	
iubtotal (95% CI) iotal events leterogeneity: Chi ² = 1 iest for overall effect: Z .1.2 DES loudriot et al 2011 :ARDIA 2010 :XCEL 2016 :REEDOM 2012 E MANS 2008 IOBLE 2016 :RECOMBAT 2011	1740 18 .00, df = 4 (p = 0. 2 = 2.17 (p = 0.03) 0 100 1 254 5 948 3 953 0 52 1 593 0 300	$\begin{array}{c} 1765\\ 34\\ 91); \ ^2 = 0\%\\ 2 & 101\\ 7 & 248\\ 12 & 957\\ 16 & 947\\ 2 & 53\\ 4 & 592\\ 2 & 300\\ \end{array}$	1.7% 4.2% 16.0% 16.0% 0.9% 10.0% 5.0%	-0.02 [-0.05, 0.01] -0.02 [-0.05, -0.00] -0.01 [-0.02, 0.00] -0.01 [-0.02, -0.00] -0.04 [-0.10, 0.02] -0.01 [-0.01, 0.00] -0.01 [-0.02, 0.00]	
ubtotal (95% CI) otal events leterogeneity: Chi ² = 1. est for overall effect: Z .1.2 DES oudriot et al 2011 ARDIA 2010 XCEL 2016 REEDOM 2012 E MANS 2008 OBLE 2016 RECOMBAT 2011 YNTAX 2009	1740 18 .00, df = 4 (p = 0. 2 = 2.17 (p = 0.03) 0 100 1 254 5 948 3 953 0 52 1 593 0 300 6 903	$\begin{array}{c} 1765\\ 34\\ 91); \ ^2 = 0\%\\ 2 & 101\\ 7 & 248\\ 12 & 957\\ 16 & 947\\ 2 & 532\\ 4 & 592\\ 2 & 300\\ 19 & 897\\ \end{array}$	1.7% 4.2% 16.0% 0.9% 10.0% 5.0% 15.1%	-0.02 [-0.05, 0.01] -0.02 [-0.05, -0.00] -0.01 [-0.02, 0.00] -0.01 [-0.02, -0.00] -0.04 [-0.10, 0.02] -0.01 [-0.01, 0.00] -0.01 [-0.02, 0.00] -0.01 [-0.03, -0.00]	-8-
ubtotal (95% CI) otal events eterogeneity: Chi ² = 1. ast for overall effect: Z 1.2 DES oudriot et al 2011 ARDIA 2010 XCEL 2016 REEDOM 2012 E MANS 2008 OBLE 2016 RECOMBAT 2011 YNTAX 2009 A-CARDIS 2013	1740 18 .00, df = 4 (p = 0. 2 = 2.17 (p = 0.03) 0 100 1 254 5 948 3 953 0 52 1 593 0 300	$\begin{array}{c} 1765\\ 34\\ 91); \ ^2 = 0\%\\ 2 & 101\\ 7 & 248\\ 12 & 957\\ 16 & 947\\ 2 & 53\\ 4 & 592\\ 2 & 300\\ \end{array}$	1.7% 4.2% 16.0% 0.9% 10.0% 5.0% 15.1% 1.7%	-0.02 [-0.05, 0.01] -0.02 [-0.05, -0.00] -0.01 [-0.02, 0.00] -0.01 [-0.02, -0.00] -0.04 [-0.10, 0.02] -0.01 [-0.01, 0.00] -0.01 [-0.02, 0.00]	
Subtotal (95% CI) Total events leterogeneity: Chi ² = 1. Test for overall effect: Z 1.2 DES Boudriot et al 2011 ARDIA 2010 EXCEL 2016 REEDOM 2012 E MANS 2008 IOBLE 2016 RECOMBAT 2011 SYNTAX 2009 A-CARDIS 2013 Subtotal (95% CI) Total events	$\begin{array}{c} 1740\\ 18\\ .00, df = 4 \ (p = 0.2\\ 2 = 2.17 \ (p = 0.03)\\ 0 \ 100\\ 1 \ 254\\ 5 \ 948\\ 3 \ 953\\ 0 \ 52\\ 1 \ 593\\ 0 \ 300\\ 6 \ 903\\ 0 \ 101\\ 4204\\ 16\end{array}$	$\begin{array}{c} 1765\\ 34\\ 91); \ l^2=0\%\\ 2 & 101\\ 7 & 248\\ 12 & 957\\ 16 & 947\\ 2 & 53\\ 4 & 592\\ 2 & 300\\ 19 & 897\\ 1 & 97\\ 4192\\ 65\end{array}$	1.7% 4.2% 16.0% 0.9% 10.0% 5.0% 15.1% 1.7%	-0.02 [-0.05, 0.01] -0.02 [-0.05, -0.00] -0.01 [-0.02, 0.00] -0.01 [-0.02, -0.00] -0.04 [-0.10, 0.02] -0.01 [-0.01, 0.00] -0.01 [-0.02, 0.00] -0.01 [-0.03, -0.00] -0.01 [-0.04, 0.02]	
Subtotal (95% CI) Total events leterogeneity: Chi ² = 1. Test for overall effect: Z .1.2 DES Boudriot et al 2011 ARDIA 2010 EXCEL 2016 REEDOM 2012 E MANS 2008 IOBLE 2016 RECOMBAT 2011 SYNTAX 2009 (A-CARDIS 2013 Subtotal (95% CI) Total events leterogeneity: Chi ² = 7.	1740 18 .00, df = 4 (p = 0. 2 = 2.17 (p = 0.03) 0 100 1 254 5 948 3 953 0 52 1 593 0 300 6 903 0 101 4204 16 .59, df = 8 (p = 0.	1765 34 91); $ ^2 = 0\%$ 2 101 7 248 12 957 16 947 2 53 4 592 2 300 19 897 1 97 4192 65 47); $ ^2 = 0\%$	1.7% 4.2% 16.0% 0.9% 10.0% 5.0% 15.1% 1.7%	-0.02 [-0.05, 0.01] -0.02 [-0.05, -0.00] -0.01 [-0.02, 0.00] -0.01 [-0.02, -0.00] -0.04 [-0.10, 0.02] -0.01 [-0.01, 0.00] -0.01 [-0.02, 0.00] -0.01 [-0.03, -0.00] -0.01 [-0.04, 0.02]	
Subtotal (95% CI) Total events leterogeneity: Chi ² = 1. Test for overall effect: Z Soudriot et al 2011 SARDIA 2010 EXCEL 2016 REEDOM 2012 E MANS 2008 IOBLE 2016 PRECOMBAT 2011 SVNTAX 2009 (A-CARDIS 2013 Subtotal (95% CI) Total events leterogeneity: Chi ² = 7. Test for overall effect: Z	1740 18 .00, df = 4 (p = 0. 2 = 2.17 (p = 0.03) 0 100 1 254 5 948 3 953 0 52 1 593 0 300 6 903 0 101 4204 16 .59, df = 8 (p = 0. 2 = 5.37 (p < 0.000)	$\begin{array}{c} 1765\\ 34\\ 91); \ ^2 = 0\%\\ 2 & 101\\ 7 & 248\\ 12 & 957\\ 16 & 947\\ 2 & 53\\ 4 & 592\\ 2 & 300\\ 19 & 897\\ 1 & 97\\ 4192\\ 65\\ 47); \ ^2 = 0\%\\ 001)\end{array}$	1.7% 4.2% 16.0% 16.0% 0.9% 10.0% 5.0% 15.1% 1.7% 70.6%	-0.02 [-0.05, 0.01] -0.02 [-0.05, -0.00] -0.01 [-0.02, 0.00] -0.01 [-0.02, -0.00] -0.01 [-0.01, 0.02] -0.01 [-0.01, 0.00] -0.01 [-0.02, 0.00] -0.01 [-0.04, 0.02] -0.01 [-0.02, -0.01]	
Subtotal (95% CI) Total events leterogeneity: Chi ² = 1. Test for overall effect: Z 1.2 DES Boudriot et al 2011 ARDIA 2010 EXCEL 2016 REEDOM 2012 E MANS 2008 IOBLE 2016 PRECOMBAT 2011 SVNTAX 2009 A-CARDIS 2013 Subtotal (95% CI) Total events leterogeneity: Chi ² = 7. Test for overall effect: Z Total (95% CI)	$\begin{array}{c} 1740\\ 18\\ .00, df = 4 \ (p = 0.2\\ 2 = 2.17 \ (p = 0.03)\\ 0 \ 100\\ 1 \ 254\\ 5 \ 948\\ 3 \ 953\\ 0 \ 52\\ 1 \ 593\\ 0 \ 300\\ 6 \ 903\\ 0 \ 101\\ 4204\\ 16\\ .59, df = 8 \ (p = 0.2\\ 2 = 5.37 \ (p < 0.000\\ 5944\\ \end{array}$	$\begin{array}{c} 1765\\ 34\\ 91); \ ^2 = 0\%\\ 2 & 101\\ 7 & 248\\ 12 & 957\\ 16 & 947\\ 2 & 53\\ 4 & 592\\ 2 & 300\\ 19 & 897\\ 1 & 97\\ 4192\\ 65\\ 47); \ ^2 = 0\%\\ 001)\\ \end{array}$	1.7% 4.2% 16.0% 16.0% 0.9% 10.0% 5.0% 15.1% 1.7% 70.6%	-0.02 [-0.05, 0.01] -0.02 [-0.05, -0.00] -0.01 [-0.02, 0.00] -0.01 [-0.02, -0.00] -0.04 [-0.10, 0.02] -0.01 [-0.01, 0.00] -0.01 [-0.02, 0.00] -0.01 [-0.03, -0.00] -0.01 [-0.04, 0.02]	* *
ubtotal (95% CI) btal events eterogeneity: Chi ² = 1. est for overall effect: Z 1.2 DES oudriot et al 2011 ARDIA 2010 XCEL 2016 REEDOM 2012 E MANS 2008 OBLE 2016 RECOMBAT 2011 YNTAX 2009 A-CARDIS 2013 ubtotal (95% CI) btal events eterogeneity: Chi ² = 7 sst for overall effect: Z otal (95% CI) btal events	$\begin{array}{c} 1740\\ 18\\ .00, df = 4 \ (p = 0.)\\ 2 = 2.17 \ (p = 0.03)\\ 0 \ 100\\ 1 \ 254\\ 5 \ 948\\ 3 \ 953\\ 0 \ 52\\ 1 \ 593\\ 0 \ 300\\ 6 \ 903\\ 0 \ 101\\ 4204\\ 16\\ .59, df = 8 \ (p = 0.)\\ 2 = 5.37 \ (p < 0.000\\ 5944\\ 34\end{array}$	1765 34 $91); ^{2} = 0\%$ $2 101$ $7 248$ $12 957$ $16 947$ $2 53$ $4 592$ $2 300$ $19 897$ $1 97$ 4192 $47); ^{2} = 0\%$ $001)$ 5957	1.7% 4.2% 16.0% 16.0% 0.9% 10.0% 5.0% 15.1% 1.7% 70.6%	-0.02 [-0.05, 0.01] -0.02 [-0.05, -0.00] -0.01 [-0.02, -0.00] -0.01 [-0.02, -0.00] -0.04 [-0.10, 0.02] -0.01 [-0.02, 0.00] -0.01 [-0.03, -0.00] -0.01 [-0.04, 0.02] -0.01 [-0.02, -0.01] -0.01 [-0.01, -0.01]	
subtotal (95% CI) otal events leterogeneity: Chi ² = 1. cest for overall effect: Z .1.2 DES loudriot et al 2011 XARDIA 2010 XCEL 2016 REEDOM 2012 E MANS 2008 IOBLE 2016 PRECOMBAT 2011 YNTAX 2009 (A-CARDIS 2013 Subtotal (95% CI) otal events leterogeneity: Chi ² = 7. cest for overall effect: Z	$\begin{array}{c} 1740\\ 18\\ .00, df = 4 \ (p = 0.)\\ 2 = 2.17 \ (p = 0.03)\\ 0 \ 100\\ 1 \ 254\\ 5 \ 948\\ 3 \ 953\\ 0 \ 52\\ 1 \ 593\\ 0 \ 300\\ 6 \ 903\\ 0 \ 101\\ 4204\\ 16\\ .59, df = 8 \ (p = 0.)\\ 2 = 5.37 \ (p < 0.000\\ 5944\\ .25, df = 13 \ (p = 0.)\\ \end{array}$	1765 34 91); $ ^2 = 0\%$ 2 101 7 248 12 957 16 947 2 53 4 592 2 300 19 897 1 97 4192 47); $ ^2 = 0\%$ 001) 5957 99 0.83); $ ^2 = 0\%$	1.7% 4.2% 16.0% 16.0% 0.9% 10.0% 5.0% 15.1% 1.7% 70.6%	-0.02 [-0.05, 0.01] -0.02 [-0.05, -0.00] -0.01 [-0.02, 0.00] -0.01 [-0.02, -0.00] -0.01 [-0.01, 0.02] -0.01 [-0.01, 0.00] -0.01 [-0.02, 0.00] -0.01 [-0.04, 0.02] -0.01 [-0.02, -0.01]	

Figure1 – Stent versus CABG: 30 days mortality (top) and stroke (bottom). The size of each box is proportional to the number of patients of the trial. The bars represent 95% confidence interval. The diamond represents the syntheses of results. DES: trials of the drug-eluting stent era. BMS: trials of the bare-metal stent trials era. CABG: coronary artery bypass grafting. ARTS: Arterial Revascularization Therapies Study; AWESOME: Angina with extremely severe outcomes; ERACI II: Argentine randomized study: coronary angioplasty with stenting versus coronary bypass surgery in patients with multi-vessel disease; MASS II: Medicine, Angioplasty, or Surgery Study; SOS: Stent or Surgery trial; BEST: Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients with Multi-vessel Coronary Artery; Boldriot, trial of Boldriot et al: J Am Coll Cardiol. 2011; 57: 538-545. CARPia: Coronary artery revascularization in diabetic; LE MANS: Left main coronary artery stenting; EXCEL: Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization; FREEDOM: Future Revascularization Evaluation in Patients with Diabetes Mellitus NOBLE, Nordic-Baltic-British Left Main Revascularization Study; PRECOMBAT: Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease; SYNTAX: Synergy between PCI with Taxus and Cardiac Surgery; Va-Cards: Coronary Artery Revascularization in Diabetes in VA Hospitals.




Figure 2 – STENT versus CABG: One-year mortality (top) and late mortality (bottom). The size of each box is proportional to the number of patients of the trial. The bars represent 95% confidence interval. The diamond represents the syntheses of results. DES: trials of the drug-eluting stent era; BMS: trials of the bare-metal stent trials era; CABG: coronary artery bypass grafting; ARTS: Arterial Revascularization Therapies Study; AWESOME: Angina with extremely severe outcomes; ERACI II: Argentine randomized study: coronary angioplasty with stenting versus coronary bypass surgery in patients with multi-vessel disease; MASS II: Medicine, Angioplasty, or Surgery Study; SOS: Stent or Surgery trial; BEST: Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients with Multi-vessel Coronary Artery; Boldriot, trial of Boldriot et al: J Am Coll Cardiol. 2011; 57: 538-545. CARPia: Coronary artery revascularization in diabetic; LE MANS: Left main coronary artery stenting; EXCEL: Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization; FREEDOM: Future Revascularization Evaluation in Patients with Diabetes Mellitus; NOBLE: Nordic-Baltic-British Left Main Revascularization Study; PRECOMBAT: Premier of Randomized Comparison of Bypass Surgery; Va-Cards: Coronary Artery Disease; SYNTAX: Synergy between PCI with Taxus and Cardiac Surgery; Va-Cards: Coronary Artery Revascularization in Diabetes in VA Hospitals.

	Stent		CAB	G		Risk Difference	Risk Difference
tudy or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI Year	M-H, Fixed, 95% Cl
on fatal MI (one year)							
RACI II 2001	5	225	15	225	4.2%	-0.04 [-0.08, -0.01] 2001	
RTS 2001	30	600	25	605	11.2%	0.01 [-0.01, -0.03] 2001	
OS 2002	34	488	14	500	9.1%	0.04 [0.01, 0.07] 2002	
ASS II 2004	18	205	4	203	3.8%	0.07 [0.02, 0.11] 2004	-
E MANS 2008	52	52	52	52	1.0%	0.00 [-0.04, 0.04] 2008	_ _
YNTAX 2009	43	891	28	849	16.1%	0.02 [-0.00, 0.03] 2009	
ARDIA 2010	25	254	14	254	4.7%	0.04 [-0.00, 0.09] 2010	
RECOMBAT 2011	4	300	3	300	5.6%	0.00 [-0.01, 0.02] 2011	+
oudriot et al 2011	3	100	4	101	1.9%	-0.01 [-0.06, 0.04] 2011	0
REEDOM 2012	62	953	42	953	17.6%	0.02 [0.00, 0.04] 2012	-0-
A-CARDIS 2013	3	101	13	97	1.8%	-0.10 [-0.18, -0.03] 2013	.
EST 2015	21	300	12	300	5.6%	0.03 [-0.01, 0.07] 2015	
XCEL 2016	47	948	62	947	17.5%	-0.02 [-0.04, 0.01] 2016	-8-
otal (95% CI)		5417		5386	100.0%	0.01 [0.00, 0.02]	
otal (95% CI) otal events	347	5417	288	5386	100.0%	0.01 [0.00, 0.02]	•
otal events eterogeneity: Chi ² = 4	1.05, df = 1	2 (p < 0			100.0%	0.01 [0.00, 0.02]	• • • • • • • • • • • • • • • • • • •
otal events	1.05, df = 1	2 (p < 0			100.0%	0.01 [0.00, 0.02]	-0.2 -0.1 0 0.1 0.2
otal events eterogeneity: Chi ² = 4	1.05, df = 1	2 (p < 0			100.0%	0.01 [0.00, 0.02]	-0.2 -0.1 0 0.1 0.2 Favours stent Favours CABG
otal events eterogeneity: Chi ² = 4	1.05, df = 12 = 2.57 (p =	2 (p < 0			100.0%	0.01 [0.00, 0.02]	
otal events eterogeneity: Chi ² = 4 est for overall effect: Z	1.05, df = 12 = 2.57 (p =	2 (p < 0			100.0% 4.9%	0.01 [0.00, 0.02]	
otal events eterogeneity: Chi ² = 4 est for overall effect: Z on fatal MI (late result	1.05, df = 12 : = 2.57 (p = s)	2 (p < 0 0.01)	1.0001); l ²	= 71%			
otal events eterogeneity: Chi ² = 4 est for overall effect: Z on fatal MI (late result RACI II 2001	1.05, df = 12 = 2.57 (p = s)	2 (p < 0 0.01) 225	0.0001); I ² 16	= 71%	4.9%	-0.04 [-0.08, 0.01] 2001	
otal events eterogeneity: Chi ² = 4 est for overall effect: Z on fatal MI (late result RACI II 2001 RTS 2001	1.05, df = 12 = 2.57 (p = s) 8 51	2 (p < 0 0.01) 225 600	1.0001); l ² 16 39	= 71% 225 605	4.9% 13.9%	-0.04 [-0.08, 0.01] 2001 0.02 [-0.01, 0.05] 2001	
otal events eterogeneity: Chi ² = 4 est for overall effect: Z on fatal MI (late result RACI II 2001 RTS 2001 ASS II 2004	1.05, df = 12 = 2.57 (p = s) 8 51 23	2 (p < 0 0.01) 225 600 205	16 39 17	= 71% 225 605 203	4.9% 13.9% 4.4%	-0.04 [-0.08, 0.01] 2001 0.02 [-0.01, 0.05] 2001 0.03 [-0.03, 0.09] 2004	
otal events eterogeneity: Chi ² = 4 est for overall effect: Z on fatal MI (late result RACI II 2001 RTS 2001 ASS II 2004 E MANS 2008	1.05, df = 12 = 2.57 (p = s) 8 51 23 5	2 (p < 0 0.01) 225 600 205 52	16 39 17 6	= 71% 225 605 203 53	4.9% 13.9% 4.4% 1.1%	-0.04 [-0.08, 0.01] 2001 0.02 [-0.01, 0.05] 2001 0.03 [-0.03, 0.09] 2004 -0.02 [-0.13, 0.10] 2008	Favours stent Favours CABG
otal events eterogeneity: Chi ² = 4 est for overall effect: Z on fatal MI (late result: RACI II 2001 RTS 2001 ASS II 2004 E MANS 2008 YNTAX 2009	1.05, df = 12 = 2.57 (p = s) 8 51 23 5 123	2 (p < 0 0.01) 225 600 205 52 903	16 39 17 6 93	= 71% 225 605 203 53 897	4.9% 13.9% 4.4% 1.1% 19.5%	-0.04 [-0.08, 0.01] 2001 0.02 [-0.01, 0.05] 2001 0.03 [-0.03, 0.09] 2004 -0.02 [-0.13, 0.10] 2008 0.03 [0.00, 0.06] 2009	Favours stent Favours CABG
otal events eterogeneity: Chi ² = 4 est for overall effect: Z on fatal MI (late result: RACI II 2001 RTS 2001 ASS II 2004 E MANS 2008 YNTAX 2009 RECOMBAT 2011	1.05, df = 12 = 2.57 (p = s) 8 51 23 5 123 6	2 (p < 0 0.01) 225 600 205 52 903 300	16 39 17 6 93 5	= 71% 225 605 203 53 897 300	4.9% 13.9% 4.4% 1.1% 19.5% 6.5%	-0.04 [-0.08, 0.01] 2001 0.02 [-0.01, 0.05] 2001 0.03 [-0.03, 0.09] 2004 -0.02 [-0.13, 0.10] 2008 0.03 [0.00, 0.06] 2009 0.00 [-0.02, 0.02] 2011	Favours stent Favours CABG
otal events eterogeneity: Chi ² = 4 est for overall effect: Z on fatal MI (late result RACI II 2001 RTS 2001 ASS II 2004 E MANS 2008 YNTAX 2009 RECOMBAT 2011 REEDOM 2012	1.05, df = 12 = 2.57 (p = s) 8 51 23 5 123 6 98	2 (p < 0 0.01) 225 600 205 52 903 300 953	16 39 17 6 93 5 48	= 71% 225 605 203 53 897 300 947	4.9% 13.9% 4.4% 1.1% 19.5% 6.5% 20.5%	-0.04 [-0.08, 0.01] 2001 0.02 [-0.01, 0.05] 2001 0.03 [-0.03, 0.09] 2004 -0.02 [-0.13, 0.10] 2008 0.03 [0.00, 0.06] 2009 0.00 [-0.02, 0.02] 2011 0.05 [0.03, 0.08] 2012	Favours stent Favours CABG
otal events eterogeneity: Chi ² = 4 est for overall effect: Z on fatal MI (late result RACI II 2001 RTS 2001 ASS II 2004 E MANS 2008 YNTAX 2009 RECOMBAT 2011 REEDOM 2012 EST 2015	1.05, df = 12 = 2.57 (p = s) 8 51 23 5 123 6 98 21	2 (p < 0 0.01) 225 600 205 52 903 300 953 438	1.0001); I ² 16 39 17 6 93 5 48 12	= 71% 225 605 203 53 897 300 947 442	4.9% 13.9% 4.4% 1.1% 19.5% 6.5% 20.5% 20.6%	-0.04 [-0.08, 0.01] 2001 0.02 [-0.01, 0.05] 2001 0.03 [-0.03, 0.09] 2004 -0.02 [-0.13, 0.10] 2008 0.03 [0.00, 0.06] 2009 0.00 [-0.02, 0.02] 2011 0.05 [0.03, 0.08] 2012 0.02 [-0.00, 0.05] 2015	Favours stent Favours CABG
otal events eterogeneity: Chi ² = 4 est for overall effect: Z on fatal MI (late result RACI II 2001 RTS 2001 ASS II 2004 E MANS 2008 YNTAX 2009 RECOMBAT 2011 REEDOM 2012 EST 2015 XCEL 2016	1.05, df = 12 = 2.57 (p = s) 8 51 23 5 123 6 98 21	2 (p < 0 0.01) 225 600 205 52 903 300 953 438 948	1.0001); I ² 16 39 17 6 93 5 48 12	= 71% 225 605 203 53 897 300 947 442 957	4.9% 13.9% 4.4% 1.1% 19.5% 6.5% 20.5% 20.6%	-0.04 [-0.08, 0.01] 2001 0.02 [-0.01, 0.05] 2001 0.03 [-0.03, 0.09] 2004 -0.02 [-0.13, 0.10] 2008 0.03 [0.00, 0.06] 2009 0.00 [-0.02, 0.02] 2011 0.05 [0.03, 0.08] 2012 0.02 [-0.00, 0.05] 2015 -0.00 [-0.03, 0.02] 2016	Favours stent Favours CABG
otal events eterogeneity: Chi ² = 4 est for overall effect: Z on fatal MI (late result: RACI II 2001 RTS 2001 ASS II 2004 E MANS 2008 YNTAX 2009 RECOMBAT 2011 REEDOM 2012 EST 2015 XCEL 2016 otal (95% CI)	1.05, df = 12 = 2.57 (p = s) 8 51 23 5 123 6 98 21 72 407	2 (p < 0 0.01) 225 600 205 52 903 300 953 438 948 4624	1.0001); 1 ² 16 39 17 6 93 5 48 12 77 313	= 71% 225 605 203 53 897 300 947 442 957 4629	4.9% 13.9% 4.4% 1.1% 19.5% 6.5% 20.5% 20.6%	-0.04 [-0.08, 0.01] 2001 0.02 [-0.01, 0.05] 2001 0.03 [-0.03, 0.09] 2004 -0.02 [-0.13, 0.10] 2008 0.03 [0.00, 0.06] 2009 0.00 [-0.02, 0.02] 2011 0.05 [0.03, 0.08] 2012 0.02 [-0.00, 0.05] 2015 -0.00 [-0.03, 0.02] 2016	Favours stent Favours CABG
otal events eterogeneity: Chi ² = 4 est for overall effect: Z on fatal MI (late result RACI II 2001 RTS 2001 ASS II 2004 E MANS 2008 YNTAX 2009 RECOMBAT 2011 REEDOM 2012 EST 2015 XCEL 2016 otal (95% CI) otal events	1.05, df = 12 = 2.57 (p = s) 8 51 23 5 123 6 98 21 72 407 1.45, df = 8	2 (p < 0 0.01) 225 600 205 52 903 300 953 438 948 4624 (p = 0.0	1.0001); 1 ² 16 39 17 6 93 5 48 12 77 313 006); 1 ² = 6	= 71% 225 605 203 53 897 300 947 442 957 4629	4.9% 13.9% 4.4% 1.1% 19.5% 6.5% 20.5% 20.6%	-0.04 [-0.08, 0.01] 2001 0.02 [-0.01, 0.05] 2001 0.03 [-0.03, 0.09] 2004 -0.02 [-0.13, 0.10] 2008 0.03 [0.00, 0.06] 2009 0.00 [-0.02, 0.02] 2011 0.05 [0.03, 0.08] 2012 0.02 [-0.00, 0.05] 2015 -0.00 [-0.03, 0.02] 2016	Favours stent Favours CABG

Figure 3 – Stent versus CABG: Acute myocardial infarct at one year (top) and after three or more years (bottom). The size of each box is proportional to the number of patients of the trial. The bars represent 95% confidence interval. The diamond represents the syntheses of results. DES: trials of the drug-eluting stent era; BMS: trials of the bare-metal stent trials era; CABG: coronary artery bypass grafting; ARTS: Arterial Revascularization Therapies Study; AWESOME: Angina with extremely severe outcomes; ERACI II: Argentine randomized study: coronary angioplasty with stenting versus coronary bypass surgery in patients with multi-vessel disease; MASS II: Medicine, Angioplasty, or Surgery Study; SOS: Stent or Surgery trial; BEST: Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients with Multi-vessel Coronary artery seludiot, trial of Boldriot et al: J Am Coll Cardiol. 2011; 57: 538-545. CARDia: Coronary artery revascularization in diabetic; LE MANS: Left main coronary artery stenting; EXCEL: Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization; FREEDOM: Future Revascularization revaluation in Patients with Diabetes Mellitus; NOBLE: Nordic-Baltic-British Left Main Coronary Artery Disease; SYNTAX: Synergy between PCI with Taxus and Cardiac Surgery; Va-Cards: Coronary Artery Revascularization in Diabetes in VA Hospitals.

Benedetto et al excluded LMCAD (that presented similar results of mortality with the two methods of revascularization) and BMS trials (that involved patients with less complex CAD), did not include AWESOME and included two years results of VaCards. Another reason for the significant worse comparative results of PCI-stent in the meta-analysis of Benedetto et al. was that diabetics represented 66% of their population. Recently a pooled analysis of an individual database from 11 trials was published by Head et al.³⁵ and their overall results are similar to ours. Small differences can be explained by the fact that they included late results of VACards and did not include AWESOME, CARDia, Boldriot and LEMANS.

LMCAD was, for a long time, an indication type III for PCI, but this concept began to change after four trials showed similar results in mortality.^{11,12,16,17} However, AHA/ACC guidelines have accepted PCI only as class IIA or IIB indication for LMCAD and yet, only for patients at high surgical risk. In the present study, we found results similar in mortality, while the incidence of stroke was lower, favouring PCI. Our findings are similar to the collaborative study of Head et al and to the meta-analysis of Palmerini et al.³² This study provided also mortality results in subgroups, showing that in patients with low SYNTAX SCORE there was a trend to higher long-term mortality with CABG (HR, 0.68, CI 0.43-1.08; p = 0.09); intermediate SYNTAX score patients had similar

Study or Subgroup	Stent Events	-	CAB Events	-	Weight	Risk Difference M-H, Fixed, 95% Cl	Risk Difference M-H, Fixed, 95% Cl
One year mortality							
Boudriot et al 2011	2	100	5	101	4.3%	-0.03 [-0.08, 0.02]	
EXCEL 2016	38	948	38	957	40.5%	0.00 [-0.02, 0.02]	
LE MANS 2008	1	52	4	53	2.2%	-0.06 [-0.14, 0.02]	_
NOBLE 2016	9	592	17	592	25.2%	-0.01 [-0.03, 0.00]	
PRECOMBAT 2011	6	300	8	300	12.8%	-0.01 [-0.03, 0.02]	
SYNTAXLM 2013	15	357	15	348	15.0%	-0.00 [-0.03, 0.03]	
Total (95% CI)		2349		2351	100.0%	-0.01 [-0.02, 0.00]	•
Total events	71		87				•
Iotal events	11						
Heterogeneity: Chi ² = 3.		= 0.60);				<u> </u>	
	64, df = 5 (p					-0.2	-0.1 0 0.1 0 Favours stent Favours CABG
Heterogeneity: Chi ² = 3.	64, df = 5 (p					-0.2	
Heterogeneity: Chi ² = 3. Test for overall effect: Z	64, df = 5 (p			903	41.6%	⊢	
Heterogeneity: Chi ² = 3. Test for overall effect: Z Late mortality	64, df = 5 (p = 1.29 (p = 0).20)	l ² = 0%	903 53	41.6% 2.4%		
Heterogeneity: Chi ² = 3. Test for overall effect: Z Late mortality EXCEL 2016	64, df = 5 (p = 1.29 (p = 0 71	913	l ² = 0%			0.02 [-0.00, 0.04]	
Heterogeneity: Chi ² = 3. Test for overall effect: Z Late mortality EXCEL 2016 LE MANS 2008	64, df = 5 (p = 1.29 (p = 0 71 11	913 52	l ² = 0%	53	2.4%	0.02 [-0.00, 0.04] -0.09 [-0.26, 0.08]	
Heterogeneity: Chi ² = 3. Test for overall effect: Z Late mortality EXCEL 2016 LE MANS 2008 NOBLE 2016	64, df = 5 (p = 1.29 (p = 0 71 11 36	913 52 592	1 ² = 0%	53 592	2.4% 27.1%	0.02 [-0.00, 0.04] -0.09 [-0.26, 0.08] 0.01 [-0.02, 0.03]	
Heterogeneity: Chi ² = 3. Test for overall effect: Z Late mortality EXCEL 2016 LE MANS 2008 NOBLE 2016 PRECOMBAT 2011	64, df = 5 (p = 1.29 (p = C 71 11 36 17	913 52 592 279	1 ² = 0%	53 592 275	2.4% 27.1% 12.7%	0.02 [-0.00, 0.04] -0.09 [-0.26, 0.08] 0.01 [-0.02, 0.03] -0.02 [-0.07, 0.02]	
Heterogeneity: Chi ² = 3. Test for overall effect: Z Late mortality EXCEL 2016 LE MANS 2008 NOBLE 2016 PRECOMBAT 2011 SYNTAXLM 2013	64, df = 5 (p = 1.29 (p = C 71 11 36 17	913 52 592 279 357	1 ² = 0%	53 592 275 348	2.4% 27.1% 12.7% 16.2%	0.02 [-0.00, 0.04] -0.09 [-0.26, 0.08] 0.01 [-0.02, 0.03] -0.02 [-0.07, 0.02] -0.03 [-0.08, 0.02]	
Heterogeneity: Chi ² = 3. Test for overall effect: Z Late mortality EXCEL 2016 LE MANS 2008 NOBLE 2016 PRECOMBAT 2011 SYNTAXLM 2013 Total (95% CI)	64, df = 5 (p = 1.29 (p = 0 71 11 36 17 42 177	913 52 592 279 357 2193	1 ² = 0% 53 16 33 23 50 175	53 592 275 348	2.4% 27.1% 12.7% 16.2%	0.02 [-0.00, 0.04] -0.09 [-0.26, 0.08] 0.01 [-0.02, 0.03] -0.02 [-0.07, 0.02] -0.03 [-0.08, 0.02]	

Figure 4 – Stent versus CABG in left main coronary artery disease: one-year mortality (top) and long-term mortality (bottom). The size of each box is proportional to the number of patients of the trial. The bars represent 95% confidence interval. The diamond represents the syntheses of results. ULMCAD: unprotected left main coronary artery disease. CABG: coronary artery bypass graft. LE MANS: Left Main coronary artery stenting study; SYNTAX LEMANS: subgroup of ULMCAD of SYNTAX (Synergy between PCI with Taxus and Surgery); PRECOMBAT: Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease; EXCEL: Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization; NOBLE: Nordic-Baltic-British Left Main Revascularization Study. Boldriot: Boldriot et al: J Am Coll Cardiol. 2011; 57: 538-545.

results (HR 1.16, Cl 0.51-264, p = 0.49). Considering this, we believe that PCI indications for LMCAD in AHA/ACC guidelines may be modified in near future.

Diabetic patients are a present challenge for PCI. A more diffuse atherosclerotic disease is a possible explanation for the worse comparative results of PCI in this population. Our results suggest that there is still a superiority of surgery over PCI in long-term mortality, even in the DES era. There is a hypothesis that the greater mortality of PCI compared to CABG in diabetic patients may be attributed to the presence of more complex lesions in diabetic patients and, not to the metabolic disturbance. The fact that in the subgroup analysis of MACCE results (Figure 5) the meta-Adjusted value was 0.09 (adjusted for SYNTAX score) supports this hypothesis.

This review was not aimed to compare the results of BMS and DES for several reasons: in BMS trials patients had less complex angiographic lesions (average of 2.3 stents per patient in ARTS and SOS trials versus 3.8 stents per patient in SYNTAX, FREEDOM, BEST, PRECOMBAT and CARDia trials) and had a small percentage of diabetic patients. Otherwise, medical adjunctive treatment and results of surgery for patients with failed PCI also evolved. But the good comparative results of PCI in BMS era trials suggest that for patients with less complex lesions, or patients with unstable angina (ERACI II trial) or high surgical risk (AWESOME trial) initial PCI is a good alternative to CABG.

In terms of major adverse composite events, the analysis of subgroups showed that diabetes and a high SYNTAX score were the most important factors to influence adversely the results of PCI. Presence of left ventricular dysfunction did not influence the results, but the number of patients with this finding was small. A high SYNTAX score was an independent risk factor for adverse outcomes, even when adjusted for diabetes, but diabetes was not an independent risk factor for adverse outcomes when adjusted for SYNTAX score.

In the present review despite the clear superiority of CABG in the outcome of new revascularization, it is possible to notice the progressive improvement of PCI results. This was particularly striking when we consider the outcome "new revascularization by alternative procedures", in which there was a tendency to superiority of PCI in the DES era.

The evidence presented here should be used to inform patients, helping them in choosing the more adequate form of revascularization in multi-vessel and LMCAD. Some patients may prefer having PCI to avoid the higher morbidity and short-term mortality of surgery. Other patients may put greater emphasis on the superiority of surgery regarding long-term mortality. However, PCI using second generation DES may still be considered as an alternative to CABG,

Study or Subgroup 1.7.1 Diabetic		BG s Total Weigh	Risk Difference at M-H, Fixed, 95% CI Year	Risk Difference M-H, Fixed, 95% Cl
FREEDOM 2012 EXCEL 2016 LEE 2017 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect:	94 534 7 1743 402 30 4.26, df = 2 (p = 0.12); I ²	7 259 1.49 8 532 2.99 1738 9.5 9 4	6 0.02 [-0.05, 0.09] 2016 6 0.03 [-0.01, 0.07] 2017	
Test for overall effect: MetaAdjusted p value for D MetaAdjusted p value for D	168 1107 13 1799 254 22 1.72, df = 1 (p = 0.19); I ²	1814 9.99 3 = 42% and Sex) ion fraction)	6 0.03 [0.00, 0.06] 2017	•
1.7.3 Aged EXCEL 2016 LEE 2017 Subtotal (95% CI) Total events	82 466 6 178 864 15 1330 260 22 0.01, df = 1 (p = 0.91); l ²	7 463 2.59 4 898 4.89 1361 7.4 9	 0.03 [-0.02, 0.08] 2016 0.03 [-0.00, 0.07] 2017 0.03 [0.00, 0.06] 	•
Test for overall effect:	83 777 5 1259 138 12 4.25, df = 1 (p = 0.04); l ²	= 76%	6 0.03 -0.00, 0.06 2017	•
	188 698 11 94 722 10 192 1222 16 2642 474 32 13.33, df = 2 (p = 0.01); Z = 3.29 (p = 0.0010)	7 742 4.09 1 1264 6.89 2664 14.5 9 6	6 -0.01 [-0.05, 0.02] 2016 0.03 [0.00, 0.06] 2017	
1.7.6 Female FREEDOM 2012 EXCEL 2016 LEE 2017 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect	70 419 5 901 180 14 0.61, df = 2 (p = 0.74); l ²	8 215 1.29 2 375 2.29 879 4.99	6 0.06 [-0.01, 0.13] 2016 6 0.03 [-0.02, 0.08] 2017	
1.7.7 Low ejection fr FREEDOM 2012 EXCEL 2016 LEE 2017 Subtotal (95% CI) Total events	13 21 20 111 2 19 68 1 200 52 3.67, df = 2 (p = 0.16); l ²	3 11 0.19 0 115 0.69 6 66 0.49 192 1.1 9 9	6 0.01 [-0.09, 0.11] 2016 6 0.04 [-0.11, 0.19] 2017	
Test for overall effect:	143 620 11 109 782 11 160 1202 14 2604 412 36 3.04, df = 2 (p = 0.22); I ²	1 786 4.9 1 1255 7.7 2670 16.6 7 = 34%	6 -0.00 [-0.04, 0.03] 2016 6 0.02 [-0.01, 0.05] 2017	•
1.7.9 Syntax \leq 22 FREEDOM 2012 EXCEL 2016 LEE 2017 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect:	75 329 5 28 294 4 77 613 6 1236 180 17 5.29, df = 2 (p = 0.07); F	8 340 2.15 6 364 2.05 6 570 3.75 1274 7.9 0	6 -0.03 [-0.08, 0.02] 2016 6 0.01 [-0.03, 0.05] 2017	
1.7.11 Syntax ≥ 32 FREEDOM 2012 EXCEL 2016 LEE 2017 Subtotal (95% Cl) Total events Heterogeneity: Chi ² =	37 202 3		6 0.04 [-0.03, 0.12] 2016 6 0.06 [0.01, 0.11] 2017	

Figure 5 – Stent versus CABG: risk difference of long-term major composite adverse outcomes (MACCE) in subgroups. The size of each box is proportional to the number of patients of the subgroups. The bars represent 95% confidence interval. The diamond represents the syntheses of results. CABG: coronary artery bypass grafting. LEE = Lee et al, J Am Coll Cardiol Intv 2016; 9:2481–9 (Meta-analysis of individual patient data of SYNTAX, PRECOMBAT and BEST); EXCEL: Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization; FREEDOM, Future Revascularization Evaluation in Patients with Diabetes Mellitus. Low ejection Fraction was defined as < 50% in EXCEL and as < 40% in FREEDOM and LEE.

	Stent		CAB	G		Risk Difference	Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI Year	M-H, Fixed, 95% Cl
New reavascularization							
AWESOME 1995	24	222	9	232	3.5%	0.07 [0.02, 0.12] 1995	_
MASS II 1995	25	203	8	203	3.2%	0.08 [0.03, 0.14] 1995	
SOS 1995	100	500	30	500	7.8%	0.14 [0.10, 0.18] 1995	-8
ARTS 1996	134	605	57	605	9.5%	0.13 [0.09, 0.17] 1996	
ERACI II 1996	35	225	10	225	3.5%	0.11 [0.06, 0.17] 1996	
LE MANS 2001	15	53	5	53	0.8%	0.19 [0.04, 0.33] 2001	
CARDIA 2002	29	248	5	248	3.9%	0.10 [0.05, 0.14] 2002	— — —
PRECOMBAT 2002	18	300	10	300	4.7%	0.03 [-0.01, 0.06] 2002	- 8
BOUDRIOT 2003	14	101	6	101	1.6%	0.08 [-0.00, 0.16] 2003	
FREEDOM 2003	120	947	50	947	14.8%	0.07 [0.05, 0.10] 2003	-8-
SINTAX 2005	128	897	54	897	14.0%	0.08 0.05, 0.11 2005	-8-
VACARDS 2006	12	97	11	97	1.5%	0.01 [-0.08, 0.10] 2006	
BEST 2008	30	442	15	442	6.9%	0.03 [0.01, 0.06] 2008	-8
NOBLE 2008	69	592	44	592	9.3%	0.04 [0.01, 0.08] 2008	
EXCEL 2010	122	957	72	957	15.0%	0.05 [0.03, 0.08] 2010	-8-
Total (95% CI)		6389		6399	100.0%	0.08 [0.07, 0.09]	•
Total events	875		386				
Heterogeneity: Chi ² = 46.	.43, df = 14	(p < 0.0	001); l ² = 7	70%		-	
	.43, df = 14	(p < 0.0	001); l ² = 7	70%		-	-0.2 -0.1 0 0.1 0.2
Heterogeneity: Chi ² = 46.	.43, df = 14	(p < 0.0	001); l ² = 7	0%		-	–0.2 –0.1 0 0.1 0.2 Favours stent Favours CABG
Heterogeneity: Chi ² = 46. Test for overall effect: Z =	.43, df = 14 = 14.74 (p <	(p < 0.0) 0.00001	001); l² = 7	70%		-	
Heterogeneity: Chi ² = 46.	.43, df = 14 = 14.74 (p <	(p < 0.0) 0.00001	001); l² = 7	203	5.3%		
Heterogeneity: Chi ² = 46. Test for overall effect: Z = New reavascularization b	.43, df = 14 = 14.74 (p <	(p < 0.0) 0.00001 e procec	001); I ² = 7) lure		5.3% 13.1%		
Heterogeneity: Chi ² = 46. Test for overall effect: Z = New reavascularization b MASS II 1995	.43, df = 14 = 14.74 (p < by alternative 17	(p < 0.00 0.00001 e procec 203	001); l ² = 7 l) lure 7	203			
Heterogeneity: Chi ² = 46. Test for overall effect: Z = New reavascularization b MASS II 1995 SOS 1995	.43, df = 14 = 14.74 (p < by alternative 17 45	(p < 0.00 0.00001 e procec 203 500	001); l ² = 7 l) lure 7 25	203 500	13.1%	0.04 [0.01, 0.07] 1995	
Heterogeneity: Chi ² = 46. Test for overall effect: Z = New reavascularization b MASS II 1995 SOS 1995 ARTS 1996	.43, df = 14 = 14.74 (p < by alternative 17 45 41	(p < 0.00 0.00001 e procec 203 500 605	001); l ² = 7 l) lure 7 25 50	203 500 605	13.1% 15.9%	0.04 [0.01, 0.07] 1995 –0.01 [–0.04, 0.01] 1996	
Heterogeneity: Chi ² = 46. Test for overall effect: Z = New reavascularization b MASS II 1995 SOS 1995 ARTS 1996 LE MANS 2001	.43, df = 14 = 14.74 (p < by alternative 17 45 41 4	(p < 0.00 0.00001 e procec 203 500 605 53	001); l ² = 7 l) lure 7 25 50 5	203 500 605 53	13.1% 15.9% 1.4%	0.04 [0.01, 0.07] 1995 -0.01 [-0.04, 0.01] 1996 -0.02 [-0.12, 0.09] 2001 -0.02 [-0.04, -0.00] 2005	
Heterogeneity: Chi ² = 46. Test for overall effect: Z = New reavascularization b MASS II 1995 SOS 1995 ARTS 1996 LE MANS 2001 SINTAX 2005	.43, df = 14 = 14.74 (p < by alternative 17 45 41 4 25	(p < 0.0) 0.00001 e procec 203 500 605 53 897	001); l ² = 7 l) lure 7 25 50 5 42	203 500 605 53 897	13.1% 15.9% 1.4% 23.6%	0.04 [0.01, 0.07] 1995 -0.01 [-0.04, 0.01] 1996 -0.02 [-0.12, 0.09] 2001	
Heterogeneity: Chi ² = 46. Test for overall effect: Z = New reavascularization b MASS II 1995 SOS 1995 ARTS 1996 LE MANS 2001 SINTAX 2005 NOBLE 2008	.43, df = 14 = 14.74 (p < by alternative 17 45 41 4 25 18	(p < 0.0) 0.00001 e procec 203 500 605 53 897 592	001); ² = 7) lure 7 25 50 5 42 42 42	203 500 605 53 897 592	13.1% 15.9% 1.4% 23.6% 15.6%	0.04 [0.01, 0.07] 1995 -0.01 [-0.04, 0.01] 1996 -0.02 [-0.12, 0.09] 2001 -0.02 [-0.04, -0.00] 2005 -0.04 [-0.07, -0.02] 2008	
Heterogeneity: Chi ² = 46. Test for overall effect: Z = New reavascularization b MASS II 1995 SOS 1995 ARTS 1996 LE MANS 2001 SINTAX 2005 NOBLE 2008 EXCEL 2010	.43, df = 14 = 14.74 (p < by alternative 17 45 41 4 25 18	(p < 0.00 0.00001 e procect 203 500 605 53 897 592 957	001); ² = 7) lure 7 25 50 5 42 42 42	203 500 605 53 897 592 957	13.1% 15.9% 1.4% 23.6% 15.6% 25.1%	0.04 [0.01, 0.07] 1995 -0.01 [-0.04, 0.01] 1996 -0.02 [-0.12, 0.09] 2001 -0.02 [-0.04, -0.00] 2005 -0.04 [-0.07, -0.02] 2008 -0.03 [-0.05, -0.01] 2010	
Heterogeneity: Chi ² = 46. Test for overall effect: Z = New reavascularization b MASS II 1995 SOS 1995 ARTS 1996 LE MANS 2001 SINTAX 2005 NOBLE 2008 EXCEL 2010 Total (95% CI)	.43, df = 14 = 14.74 (p < by alternative 17 45 41 4 25 18 33 .10, df = 6 (p	(p < 0.00 0.00001 203 500 605 53 897 592 957 3807 0 = 0.000	001); ² = 7) lure 7 25 50 5 42 42 65 236	203 500 605 53 897 592 957 3807	13.1% 15.9% 1.4% 23.6% 15.6% 25.1%	0.04 [0.01, 0.07] 1995 -0.01 [-0.04, 0.01] 1996 -0.02 [-0.12, 0.09] 2001 -0.02 [-0.04, -0.00] 2005 -0.04 [-0.07, -0.02] 2008 -0.03 [-0.05, -0.01] 2010	

Figure 6 – Stent versus CABG: new revascularization (top) and new revascularization by alternative procedure (bottom). The size of each box is proportional to the number of patients of the trial. The bars represent 95% confidence interval. The diamond represents the syntheses of results. DES: trials of the drug-eluting stent era; BMS: trials of the bare-metal stent trials era; CABG: coronary artery bypass grafting; ARTS: Arterial Revascularization Therapies Study; AWESOME: Angina with extremely severe outcomes; ERACI II: Argentine randomized study: coronary angioplasty with stenting versus coronary bypass surgery in patients with multi-vessel disease; MASS II: Medicine, Angioplasty, or Surgery Study; SOS: Stent or Surgery trial; BEST: Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients with Multi-vessel Coronary artery short, trial of Boldriot et al: J Am Coll Cardiol. 2011; 57: 538-545. CARDia: Coronary artery revascularization EXALSI: Left main coronary artery stenting; EXCEL: Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization; FREEDOM: Future Revascularization Evaluation in Patients with Diabetes Mellitus; NOBLE: Nordic-Baltic-British Left Main Revascularization Study; PRECOMBAT: Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease; SYNTAX: Synergy between PCI with Taxus and Cardiac Surgery; Va-Cards: Coronary Artery Revascularization in Diabetes in VA Hospitals.

having similar mortality results, for patients with LMCAD of low or intermediate complexity (SYNTAX score < 33). This may also be the case for multi-vessel disease patients with lesions of low complexity (SYNTAX score < 23). For all other patients, particularly if diabetics, surgery remains the best form of revascularization. There is the possibility that second-generation DES and a more functional strategy, using free fractional reserve and avoiding unnecessary revascularizations will improve the comparative results of PCI in the future. The one year results of the SYNTAX II³⁶ study suggests that this will be true, but long-term follow-up is waited and a randomized trial with contemporary CABG is warranted.

The present study presents important limitations. It is a meta-analysis of published data and not a collaborative meta-analysis with access to individual data of patients. The inclusion of BMS era trials can also be criticized. It should also be noted that 30 days mortality and late mortality showed moderate heterogeneity, reducing the robustness of our results. Otherwise, our findings apply only to patients for whom revascularization may be performed using either method, without high surgical risk, no history of prior surgical revascularization, normal or near-normal ejection fraction and with the procedures carried out in institutions of excellence.




Figure 7 – Study Flow Diagram. RCT: randomized controlled trial; CABG: coronary artery bypass grafting; LAD: left anterior descending; PCI: percutaneous coronary intervention.

Conclusion

PCI using stents when compared to CABG was associated with a trend to lower mortality at 30 days, similar one-year mortality, lower incidence of stroke up to one-year, and a trend to higher long-term mortality. There was no long-term mortality difference in non-diabetics and in LMCAD patients. In terms of composite adverse outcomes, the SYNTAX score and diabetes were the most important factors to consider when choosing between the two methods of revascularization.

Author contributions

Conception and design of the research and critical revision of the manuscript for intellectual content: Andrade PJN; acquisition of data: Andrade PJN, Falcão JLAA, Falcão BAA; analysis and interpretation of the data and writing of the manuscript: Andrade PJN, Falcão JLAA, Falcão BAA, Rocha HAL; statistical analysis: Rocha HAL.

Potential Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Sources of Funding

There were no external funding sources for this study.

Study Association

This study is not associated with any thesis or dissertation work.

Ethics approval and consent to participate

This article does not contain any studies with human participants or animals performed by any of the authors.

References

- Morrison DA, Sethi G, Sacks J, Henderson W, Grover F, Sedlis S, et al. Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: a multicenter, randomized trial. Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). J Am Coll Cardiol. 2001;38(1):143-9.
- Rodriguez A, Bernardi V, Navia J, Baldi J, Grinfield L, Martinez J, et al. Argentine Randomized Study: Coronary Angioplasty with Stenting versus Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-day and one-year follow-up results. ERACI II Investigators. J Am Coll Cardiol. 2001;37(1): 51-8.
- Rodriguez AE, Baldi J, Fernández Pereira C, Navia J, Rodriguez Alemparte M, Delacasa A, et al. Five-year follow-up of the Argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II). J Am Coll Cardiol. 2005;46(4):582-8.
- Hueb W, Soares PR, Gersh BJ, Cesar LA, Luz PL, Puig LB, et al. The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J Am Coll Cardiol. 2004;43(10):1743-51.
- Hueb W, Lopes NH, Gersh BJ, Soares P, Machado LA, Jatene FB, et al. Fiveyear follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation. 2007;115(9):1082-9.
- Hueb W, Lopes N, Gersh BJ, Soares PR, Ribeiro EE, Pereira AC, et al. Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation. 2010;122(10):949-57.
- SOS investigators. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. Lancet. 2002;360(9338):965-70.
- Booth J, Clayton T, Pepper J, Nugara F, Flather M, Sigwart U, et al Randomized, controlled trial of coronary artery bypass surgery versus percutaneous coronary intervention in patients with multivessel coronary artery disease: six-year follow-up from the Stent or Surgery Trial (SoS). Circulation. 2008;118(4):381-8.
- Serruys PW, Unger F, Sousa JE, Jatene A, Bounier HJ, Schomberger JP, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med. 2001;344(15):1117-24.
- Serruys PW, Ong AT, van Herwerden LA, Sousa JE, Jatene A, Bonnier JJ, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol. 2005;46(4):575-81.
- Buszman PE, Kiesz SR, Bochenck A, Peszek-Przrya E, Szkiobka I, Debwski M, et al. Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularization. J Am Coll Cardiol. 2008;51(5):538-545.
- Serruys PW, Morice MC, Kappetei AP, Colombo A, Holmes DR, Mack MJ, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Eng J Med. 2009;360(10):961-72.
- Mohr FW, Morice MC, Kappetein AP, Feldman TE, Ståhle E, Colombo A, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013;381(9867):629-38.
- 14. Morice MC, Serruys PW, Kappetein AP, Feldman TE, Ståhle E, Colombo A, et al. Five-year outcomes in patients with left main disease treated with either percutaneous coronary intervention or coronary artery bypass grafting in

the synergy between percutaneous coronary intervention with taxus and cardiac surgery trial. Circulation. 2014;129(23):2388-94.

- Kapur A, Hall RJ, Macik IS, Qureshi AC, Butts J, de Belder M, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization In Diabetics) trial. J Am Coll Cardiol. 2010;55(5):432-40.
- Boudriot E, Thiele H, Walther T, Liebetrau C, Boeckstegers P, Pohl T, et al. Randomized comparison of percutaneous coronary intervention with Sirolimus eluting stents versus coronary artery bypass grafting in unprotected in unprotected left main stenosis. J Am Coll Cardiol. 2011;57(5):538-45.
- Park SJ, Kim YH, Park DW, Yun SC, Ahn JM, Song HG, et al. Randomized trial of stents versus bypass surgery for left main coronary artey disease. N Engl J Med. 2011;364(18):1718-27.
- Ahn JM, Roh JH, Kim YH, Park DW, Yun SC, Lee PH, et al. Randomized Trial of Stents Versus Bypass Surgery for Left Main Coronary Artery Disease: 5-Year Outcomes of the PRECOMBAT Study. J Am Coll Cardiol. 2015;65(20):2198-206.
- Kamalesh M, Shap TG, Tang C, Shunk K, Ward HB, Walsh J, et al. Percutaneous coronary intervention versus Coronary artery bypass surgery in United States veterans with diabetes. J Am Coll Cardiol. 2013,61(8):807-16.
- Farkouh ME, Dornanski M, Sleeper LA, Siami FS, Dangas G, Mack M, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;367(25):2375-84.
- 21. Park SJ, Ahn KM, Kim YH, Park DW, Yun SC, Lee JY, et al. Trial of everolimuseluting stents or bypass surgery for coronary disease. N Engl J Med. 2015; 372(13):1204-12.
- Makikallia T, Holm NR, Lindsay M, Spence MS, Erglis A, Menown IB, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomized, open-label, non-inferiority trial. Lancet. 2016;388(10061):2743-52.
- Stone GW, Sabik JF, Serruys PW, Simonton CA, Généreux P, Puskas J, et al. Everolimus-stenting or bypass surgery for left main coronary artery disease. N Engl J Med. 2016;375(23):2223-35.
- Bravata DM, Gienger AL, McDonad KM, Sundaram V, Perez MV, Varghese R, et al. Sistematic review: the comparative effectiveness of percutaneous coronary intervention and coronary artery bypass graft surgery. Ann Intern Med. 2007;147(10):703-16.
- Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet. 2009;373(9670):1190-7.
- Smit Y, Valyen J, Kopennaal H, Eefting E, Kappetein AP, Mariani MA. Percutaneous coronary invervention versus coronary artery bypass grafting: a meta-analysis. J Thorac Cardiovasc Surg. 2015;149(3):831-8.
- 27. Andrade PJ, Medeiros MM, Andrade AT, Lima AA. Coronary angioplasty versus CABG: review of randomized trials. Arq Bras Cardiol. 2011;97(3):e60-9.
- Andrade PJN, Rocha HAL, Falcão JLAA, Andrade AT, Falcão BAA. Drugeluting stents Versus Coronary Artery Bypass Grafting in Multivessel Disease and Left Main Obstruction: Meta-analysis of Randomized Clinical Trials. Int J Cardiovasc Sci. 2018;31(2):152-62.
- Lee CW, Ahn JM, Cavalcante R, Sotomi Y, Onuma Y, Suwannasom P, et al. Coronary artery bypass surgery versus drug-eluting stent implantation for left main or multi vessel coronary artery disease: a meta-analysis of individual patient data. JACC Cardiovasc Interv. 2016;9(24):2481-9.

- Cavalcante R, Sotomi Y, Lee CW, Ahn JM, Farook V, Tateish H, et al. Outcomes after Percutaneous Coronary intervention and Bypass surgery in patients with unprotected left main disease. J Am Coll Cardiol. 2016:68(10):999-1009.
- Benedetto U, Gaudino M, Ng C, Biondi-Zoccai G, Dàscenzo F, Frati G, et al. Coronary surgery is superior to drug eluting stents in multivessel disease. Systematic review and meta-analysis of contemporary randomized controlled trials. Int J Cardiol. 2016 May 1;210:19-24.
- 32. Palmerini T, Serruys P, Kappetein AP, Genereux P, Riva DD, Reggianni LB, et al. Clinical outcomes with percutaneous coronary revascularization versus coronary artery bypass grafting surgery in patients with unprotected left main coronary artery disease: a meta-analysis of six randomized trials and 4,686 patients. Am Heart J. 2017 Aug;190:54-63.
- Bangalore S, Guo Y, Samadashvili Z, Blecker S, Jinfeng X, Hannan EL. Everolimus-Eluting Stents or Bypass Surgery for Multivessel Coronary Disease. N Eng J Med. 2015;372(13):1213-22.
- 34. Tong BC, Huber JC, Ascheim DD, Puskas JD, Ferguson TB Jr, Blackstone EH, et al. Weighting composite events endpoints in clinical trials: essential evidence for the heart team. Ann Thorac Surg. 2012;94(6):1908-13.
- Head SJ, Milojevic M, Daemen J, Ahn JM, Boersma E, Christiansen EH, et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a polled analysis of individual patient data. Lancet. 2018;391(10124):939-48.
- Escaned J, Collet C, Ryan N, De Maria GL, Walsh S, Sabate M, et al. Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study. Eur Heart J. 2017;38(42):3124-34.

